Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Trinity J Bivalacqua

Showing results (31-40 of 395) with videos related to

Pageof 40
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 8, 2015
Reply to C.G. Rusthoven et alPhuoc T Tran, Trinity J Bivalacqua, Adam P Dicker
Therapeutic Advances in Urology|December 2, 2014
Management of priapism: an update for cliniciansHelen R Levey, Robert L Segal, Trinity J Bivalacqua
Urology Case Reports|April 6, 2017
Innumerable Condyloma Acuminatum Tumors of the BladderAlexandra J Murray, Trinity J Bivalacqua, Nikolai A Sopko
The Journal of Sexual Medicine|September 10, 2008
Erythropoietin promotes erection recovery after nerve-sparing radical retropubic prostatectomy: a retrospective analysisArthur L Burnett, Mohamad E Allaf, Trinity J Bivalacqua
Urologic Oncology|September 21, 2011
Metabolomics and bladder cancerMatthew E Hyndman, Jeffrey K Mullins, Trinity J Bivalacqua
Urology|July 29, 2014
Reply: To PMID 25065987Adam C Reese, Trinity J Bivalacqua, Mark P Schoenberg
Translational Andrology and Urology|April 8, 2020
Evolving therapies for Peyronie's disease: how can we work towards new drugs?Uros Milenkovic, Jolien Duponselle, Trinity J Bivalacqua, et al.
Journal of Andrology|December 4, 2010
Daily phosphodiesterase type 5 inhibitor therapy as rescue for recurrent ischemic priapism after failed androgen ablationPhillip M Pierorazio, Trinity J Bivalacqua, Arthur L Burnett
Expert Opinion on Pharmacotherapy|April 23, 2004
Vardenafil: a novel type 5 phosphodiesterase inhibitor for the treatment of erectile dysfunctionMuammer Kendirci, Trinity J Bivalacqua, Wayne J G Hellstrom
BJU International|August 6, 2008
Bladder cancer and the aluminium industry: a reviewThomas J Guzzo, Trinity J Bivalacqua, Mark P Schoenberg
Pageof 40

Showing results (31-40 of 395) with videos related to

Sort By:
Pageof 40
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 8, 2015
Reply to C.G. Rusthoven et alPhuoc T Tran, Trinity J Bivalacqua, Adam P Dicker
Therapeutic Advances in Urology|December 2, 2014
Management of priapism: an update for cliniciansHelen R Levey, Robert L Segal, Trinity J Bivalacqua
Urology Case Reports|April 6, 2017
Innumerable Condyloma Acuminatum Tumors of the BladderAlexandra J Murray, Trinity J Bivalacqua, Nikolai A Sopko
The Journal of Sexual Medicine|September 10, 2008
Erythropoietin promotes erection recovery after nerve-sparing radical retropubic prostatectomy: a retrospective analysisArthur L Burnett, Mohamad E Allaf, Trinity J Bivalacqua
Urologic Oncology|September 21, 2011
Metabolomics and bladder cancerMatthew E Hyndman, Jeffrey K Mullins, Trinity J Bivalacqua
Urology|July 29, 2014
Reply: To PMID 25065987Adam C Reese, Trinity J Bivalacqua, Mark P Schoenberg
Translational Andrology and Urology|April 8, 2020
Evolving therapies for Peyronie's disease: how can we work towards new drugs?Uros Milenkovic, Jolien Duponselle, Trinity J Bivalacqua, et al.
Journal of Andrology|December 4, 2010
Daily phosphodiesterase type 5 inhibitor therapy as rescue for recurrent ischemic priapism after failed androgen ablationPhillip M Pierorazio, Trinity J Bivalacqua, Arthur L Burnett
Expert Opinion on Pharmacotherapy|April 23, 2004
Vardenafil: a novel type 5 phosphodiesterase inhibitor for the treatment of erectile dysfunctionMuammer Kendirci, Trinity J Bivalacqua, Wayne J G Hellstrom
BJU International|August 6, 2008
Bladder cancer and the aluminium industry: a reviewThomas J Guzzo, Trinity J Bivalacqua, Mark P Schoenberg
Pageof 40